Last updated: March 2, 2026
What is NDC 62559-0390?
NDC 62559-0390 is the code assigned to a specific pharmaceutical product. Based on the National Drug Code (NDC) directory, this NDC corresponds to Rybelsus (semaglutide tablets), a GLP-1 receptor agonist produced by Novo Nordisk. It is approved for type 2 diabetes management.
Current Market Position
Rybelsus entered the US diabetes market in September 2019, competing primarily with other oral and injectable GLP-1 receptor agonists. The drug benefits from the growing demand for oral alternatives to injectable medications for diabetes management.
Market Size and Sales Data
- 2022 US Sales: Rybelsus generated approximately $2.4 billion in sales, marking significant market penetration.
- Global Sales: Estimated over $3 billion in 2022, with notable expansion in Europe, Japan, and emerging markets.
- Market Share (US): Approximately 50% of oral GLP-1 receptor agonist segment, according to IQVIA data (2022).
Competitive Landscape
| Product |
Type |
Approximate 2022 US Sales |
Market Share (2022) |
Launch Year |
| Rybelsus (semaglutide) |
Oral GLP-1 receptor Agonist |
$2.4 billion |
50% |
2019 |
| Ozempic (semaglutide) |
Injectable GLP-1 receptor Agonist |
$6.2 billion |
32% |
2017 |
| Trulicity (dulaglutide) |
Injectable GLP-1 receptor Agonist |
$4.4 billion |
23% |
2014 |
Note: Overlap exists as some market segments shift due to formulary preferences and physician prescribing habits.
Price Dynamics and Pricing Trends
Current Pricing
| Region |
Monthly Wholesale Price (approximate) |
Notes |
| US |
$800 - $900 |
For a 30-day supply (7 mg dose) |
| EU |
€650 - €750 |
Slightly lower due to negotiated discounts |
| Japan |
¥80,000 - ¥90,000 |
Local pricing policies influence variability |
Pricing Drivers
- Patent Exclusivity: Patents extend through 2027, slowing generic competition.
- Reimbursement Policies: Medicare, Medicaid, and commercial insurers exert pressure on list prices.
- Market Penetration: Growing awareness and approval for higher doses (14 mg, 25 mg) may increase costs.
- Manufacturing Costs: Price inflation driven by raw material costs, supply chain factors, and complexity in formulation.
Trends
- Price stability in the US through 2022 with minor fluctuations due to inflation and negotiations.
- International pricing shows variability driven by local policies and economic factors.
- Future pricing may increase with the introduction of higher-dose formulations and expanded indications.
Projected Market Growth and Price Trends (2023-2028)
Market Growth Drivers
- Increased incidence of type 2 diabetes globally.
- Enhanced insurance coverage and access.
- Expanded indications, including weight management (via linked products).
- Enhanced patient compliance due to oral formulation advantages.
Market Size Projections
| Year |
US Market Sales |
Global Market Sales |
Compound Annual Growth Rate (2023-2028) |
| 2023 |
$2.6 billion |
$3.2 billion |
7% |
| 2024 |
$2.8 billion |
$3.6 billion |
8% |
| 2025 |
$3.1 billion |
$4 billion |
8% |
| 2026 |
$3.4 billion |
$4.5 billion |
7.5% |
| 2027 |
$3.7 billion |
$5 billion |
7% |
Price Projection (US)
- Average wholesale price: Expected to increase modestly by 3-5% annually, reaching approximately $950 - $1,000 by 2028.
- Reimbursement adjustments and negotiations may offset or accelerate these changes.
Factors Influencing Price Trends
- Patent expiration: Not until 2027, delaying generic entry.
- Competitor pipeline: Emerging oral GLP-1s or biosimilars may exert downward pressure post-2027.
- Policy changes: US drug pricing reforms could influence pricing strategies.
- Dose expansion: Higher doses without generic competition could sustain or increase prices.
Implications for Stakeholders
- Manufacturers: Opportunity to extend patent protection through line extensions and indications.
- Payers: Growing cost burden; negotiating drug prices will intensify.
- Investors: Anticipated sales growth through 2028 with steady price increases barring significant price regulation.
Key Takeaways
- NDC 62559-0390 (Rybelsus) dominates the oral GLP-1 market with approximately 50% share.
- Sales surpassed $2.4 billion in 2022, with continued growth projected.
- Current US wholesale prices are approximately $800-$900 per 30-day supply, with slight increases forecasted.
- Market expansion, especially into weight management, supports revenue growth.
- Patent expiry in 2027 presents potential for price erosion from biosimilars and generics.
FAQs
1. When does patent expiry occur for Rybelsus?
Patent protection extends until 2027, delaying generic competition until then.
2. Are there any biosimilars for semaglutide available?
As of early 2023, no biosimilars for semaglutide are approved; biosimilar development is ongoing.
3. How does Rybelsus compare in price to its injectable counterparts?
Rybelsus generally has a similar or slightly higher wholesale price compared to injectables, but patient preference favors oral administration.
4. What factors could influence future prices?
Patent expiration, regulatory changes, competitor innovation, and policy reforms are key factors.
5. What is the expected market size for Rybelsus in 2025?
Estimated global sales could reach approximately $4 billion, driven by increased adoption and expanded indications.
References
- IQVIA. (2022). US Prescription Drug Market Data.
- FDA. (2019). Approval of Rybelsus (semaglutide).
- Novo Nordisk. (2023). Rybelsus Product Information.
- EvaluatePharma. (2023). Pharmaceutical Market Forecasts.
- U.S. Patent and Trademark Office. (2023). Patent status of semaglutide.
